Ebola Viral Infections - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ebola Viral Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H1 2015', provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ebola Viral Infections Overview 9
Therapeutics Development 10
Pipeline Products for Ebola Viral Infections - Overview 10
Pipeline Products for Ebola Viral Infections - Comparative Analysis 11
Ebola Viral Infections - Therapeutics under Development by Companies 12
Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes 16
Ebola Viral Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Ebola Viral Infections - Products under Development by Companies 21
Ebola Viral Infections - Products under Investigation by Universities/Institutes 25
Ebola Viral Infections - Companies Involved in Therapeutics Development 26
Abivax S.A. 26
AmVac AG 27
AnGes MG, Inc. 28
Canopus BioPharma Incorporated 29
Crucell N.V. 30
Etubics Corporation 31
FIT Biotech Oy 32
GeoVax Labs, Inc. 33
GlaxoSmithKline plc 34
Hemispherx Biopharma, Inc. 35
Humabs BioMed SA 36
Immune Response BioPharma, Inc. 37
Immunovaccine, Inc. 38
Inovio Pharmaceuticals, Inc. 39
Kymab Limited 40
Medicago Inc. 41
Merck & Co., Inc. 42
Microbiotix, Inc. 43
Navigen Pharmaceuticals, Inc. 44
Novavax, Inc. 45
Peregrine Pharmaceuticals, Inc. 46
SignPath Pharma Inc 47
Sihuan Pharmaceutical Holdings Group Ltd. 48
SKAU Vaccines ApS 49
Tamir Biotechnology, Inc. 50
Tekmira Pharmaceuticals Corp. 51
Toyama Chemical Co., Ltd. 52
United Therapeutics Corporation 53
Vaxart, Inc. 54
XBiotech USA, Inc. 55
Ebola Viral Infections - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
ABX-544 - Drug Profile 66
Ad5-EBOV vaccine - Drug Profile 67
AMV-711 - Drug Profile 68
ANSX-109 - Drug Profile 69
ANSX-142 - Drug Profile 70
Antibody for Ebola Viral Infection - Drug Profile 71
bavituximab - Drug Profile 72
CB-007 - Drug Profile 77
CB-008 - Drug Profile 78
DLANA-14 - Drug Profile 79
DPX-Ebola - Drug Profile 80
ebola + marburg vaccine - Drug Profile 81
ebola + rabies vaccine - Drug Profile 82
ebola [strain sudan] vaccine - Drug Profile 83
ebola [strain zaire] vaccine - Drug Profile 84
ebola [strain zaire] vaccine - Drug Profile 85
ebola [zaire] vaccine - Drug Profile 86
ebola [zaire] vaccine - Drug Profile 87
ebola vaccine - Drug Profile 88
ebola vaccine - Drug Profile 91
ebola vaccine - Drug Profile 92
ebola vaccine - Drug Profile 94
ebola vaccine - Drug Profile 95
ebola vaccine - Drug Profile 96
ebola vaccine - Drug Profile 97
ebola vaccine - Drug Profile 98
ebola vaccine - Drug Profile 100
ebola vaccine - Drug Profile 101
ebola virus like particle vaccine - Drug Profile 102
ebola virus like particle vaccine - Drug Profile 103
ET-007 - Drug Profile 104
favipiravir - Drug Profile 105
FBH-004 - Drug Profile 107
FDX-000 - Drug Profile 108
GBV-006 - Drug Profile 109
Gene Therapy for Ebola Virus Infections - Drug Profile 110
GOVXE-301 - Drug Profile 111
GOVXE-302 - Drug Profile 112
GreEMTri - Drug Profile 113
imatinib mesylate - Drug Profile 114
INO-4212 - Drug Profile 115
interferon alfa-n3 - Drug Profile 116
IRE-101 - Drug Profile 117
JK-05 - Drug Profile 118
KV-7005 - Drug Profile 119
Liposomal Curcumin - Drug Profile 120
MIL-77 - Drug Profile 122
MMCatLMC - Drug Profile 123
Monoclonal Antibodies for Ebola Viral Infections - Drug Profile 124
Monoclonal Antibodies for Viral Infections - Drug Profile 125
Monoclonal Antibody for Ebola Viral Infections - Drug Profile 127
Monoclonal Antibody for Ebola Virus Infections - Drug Profile 128
NCK-8 - Drug Profile 129
NoBola - Drug Profile 130
OS-2966 - Drug Profile 131
rintatolimod - Drug Profile 132
Small Molecules for Ebola Virus Infection - Drug Profile 134
Small Molecules for Ebola Virus Infections - Drug Profile 135
Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile 136
Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile 137
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 138
Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections - Drug Profile 139
Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile 140
Synthetic Peptides for Ebola Virus - Drug Profile 141
thiocarbazate - Drug Profile 142
TKM-100802 - Drug Profile 143
TKM-Ebola-Guinea - Drug Profile 146
TMR-004 - Drug Profile 147
UV-4B - Drug Profile 148
V-920 - Drug Profile 149
ZMAb - Drug Profile 152
ZMapp - Drug Profile 154
Ebola Viral Infections - Recent Pipeline Updates 156
Ebola Viral Infections - Dormant Projects 186
Ebola Viral Infections - Discontinued Products 188
Ebola Viral Infections - Product Development Milestones 189
Featured News & Press Releases 189
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables

Number of Products under Development for Ebola Viral Infections, H1 2015 15
Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Development by Companies, H1 2015 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Comparative Analysis by Unknown Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Development by Companies, H1 2015 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2015 30
Ebola Viral Infections - Pipeline by Abivax S.A., H1 2015 31
Ebola Viral Infections - Pipeline by AmVac AG, H1 2015 32
Ebola Viral Infections - Pipeline by AnGes MG, Inc., H1 2015 33
Ebola Viral Infections - Pipeline by Canopus BioPharma Incorporated, H1 2015 34
Ebola Viral Infections - Pipeline by Crucell N.V., H1 2015 35
Ebola Viral Infections - Pipeline by Etubics Corporation, H1 2015 36
Ebola Viral Infections - Pipeline by FIT Biotech Oy, H1 2015 37
Ebola Viral Infections - Pipeline by GeoVax Labs, Inc., H1 2015 38
Ebola Viral Infections - Pipeline by GlaxoSmithKline plc, H1 2015 39
Ebola Viral Infections - Pipeline by Hemispherx Biopharma, Inc., H1 2015 40
Ebola Viral Infections - Pipeline by Humabs BioMed SA, H1 2015 41
Ebola Viral Infections - Pipeline by Immune Response BioPharma, Inc., H1 2015 42
Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H1 2015 43
Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 44
Ebola Viral Infections - Pipeline by Kymab Limited, H1 2015 45
Ebola Viral Infections - Pipeline by Medicago Inc., H1 2015 46
Ebola Viral Infections - Pipeline by Merck & Co., Inc., H1 2015 47
Ebola Viral Infections - Pipeline by Microbiotix, Inc., H1 2015 48
Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 49
Ebola Viral Infections - Pipeline by Novavax, Inc., H1 2015 50
Ebola Viral Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 51
Ebola Viral Infections - Pipeline by SignPath Pharma Inc, H1 2015 52
Ebola Viral Infections - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2015 53
Ebola Viral Infections - Pipeline by SKAU Vaccines ApS, H1 2015 54
Ebola Viral Infections - Pipeline by Tamir Biotechnology, Inc., H1 2015 55
Ebola Viral Infections - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 56
Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2015 57
Ebola Viral Infections - Pipeline by United Therapeutics Corporation, H1 2015 58
Ebola Viral Infections - Pipeline by Vaxart, Inc., H1 2015 59
Ebola Viral Infections - Pipeline by XBiotech USA, Inc., H1 2015 60
Assessment by Monotherapy Products, H1 2015 61
Assessment by Combination Products, H1 2015 62
Number of Products by Stage and Target, H1 2015 64
Number of Products by Stage and Mechanism of Action, H1 2015 66
Number of Products by Stage and Route of Administration, H1 2015 68
Number of Products by Stage and Molecule Type, H1 2015 70
Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H1 2015 161
Ebola Viral Infections - Dormant Projects, H1 2015 191
Ebola Viral Infections - Dormant Projects (Contd..1), H1 2015 192
Ebola Viral Infections - Discontinued Products, H1 2015 193